Kymera Therapeutics (NASDAQ:KYMR) Research Coverage Started at Citigroup

Citigroup began coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $52.00 target price on the stock.

KYMR has been the subject of a number of other research reports. BTIG Research began coverage on shares of Kymera Therapeutics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective for the company. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $38.00 to $57.00 in a research report on Monday, December 2nd. Stephens restated an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Leerink Partners restated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th. Finally, HC Wainwright raised their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $56.36.

Kymera Therapeutics Stock Up 2.8 %

NASDAQ KYMR opened at $34.37 on Thursday. Kymera Therapeutics has a 52-week low of $29.07 and a 52-week high of $53.27. The business’s 50-day moving average price is $37.43 and its 200 day moving average price is $42.80. The firm has a market cap of $2.23 billion, a P/E ratio of -14.69 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. As a group, analysts anticipate that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the transaction, the chief financial officer now directly owns 201,886 shares of the company’s stock, valued at $6,147,428.70. This trade represents a 3.37 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Ellen Chiniara sold 3,129 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the transaction, the insider now directly owns 54,826 shares of the company’s stock, valued at approximately $2,288,985.50. This trade represents a 5.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 13,788 shares of company stock valued at $455,202 in the last ninety days. Corporate insiders own 15.82% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Blue Trust Inc. grew its stake in shares of Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after buying an additional 270 shares during the period. State of Wyoming acquired a new position in shares of Kymera Therapeutics during the 4th quarter valued at $45,000. GF Fund Management CO. LTD. acquired a new position in shares of Kymera Therapeutics during the 4th quarter valued at $55,000. KBC Group NV lifted its holdings in shares of Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after acquiring an additional 752 shares in the last quarter. Finally, Quarry LP acquired a new position in shares of Kymera Therapeutics during the 3rd quarter valued at $95,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.